Has Dominique Bethea received payments from drug or device companies?

Yes. Drug and device makers reported $11,669 in general payments to Dominique Bethea across 488 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Dominique Bethea did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Dominique Bethea come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Dominique Bethea

Family · Lawrenceville, GANPI 1396201885

Payments from drug & device makers

$11,669in general payments, 2019–2025

Across 488 payments — averaging $23.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$2K
Xeris Pharmaceuticals, Inc.$2K
Abbott$1K
Lilly USA, LLC$914
AstraZeneca$663
Sanofi-aventis U.S. LLC$643
plus $5K from 36 others

What the payments were for

Travel & lodging$50%
Food & beverage$11,664100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	103	$1,995
Xeris Pharmaceuticals, Inc.	62	$1,772
Abbott	13	$1,056
Lilly USA, LLC	57	$914
AstraZeneca(2 entities)	37	$663
Sanofi-aventis U.S. LLC	30	$643
Dexcom, Inc.	14	$571
Amgen	19	$490
Insulet Corporation	12	$460
Medtronic	5	$454
Corcept Therapeutics	18	$304
Tandem Diabetes Care, Inc.	12	$202
Amarin Pharma, Inc.	9	$193
Cequr Corporation	2	$191
Bayer	11	$172
Radius Health, Inc.	7	$137
AbbVie	9	$128
Amneal Pharmaceuticals LLC	8	$128
Eisai Inc.	1	$122
Boehringer Ingelheim	6	$121
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	7	$120
Mannkind Corporation	5	$118
Esperion Therapeutics, Inc.	5	$103
Ascensia Diabetes Care US Inc.	5	$84
Vivus LLC	4	$61
IBSA Pharma Inc.	3	$46
Verity Pharmaceuticals Inc.	2	$44
Recordati_rare_diseases_inc.	3	$44
Kyowa Kirin, Inc.	2	$43
Lifescan, Inc.	2	$33
Antares Pharma, Inc.	2	$32
Pfizer	2	$32
Amphastar Pharmaceuticals, Inc.	2	$31
BD	1	$29
Astellas Pharma US Inc	1	$23
BETA Bionics, Inc.	1	$22
Embecta Corp.	1	$19
Otsuka America Pharmaceutical, Inc.	1	$17
EUSA Pharma (US) LLC	1	$15
Averitas Pharma Inc.	1	$15
Merck	1	$12
Clarus Therapeutics Inc.	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,669 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	249	$450,399
MounjaroTirzepatide	107	$146,536
TrulicityDulaglutide	80	$142,900
JardianceEmpagliflozin	109	$140,123
FarxigaDapagliflozin Propanediol	89	$110,280
Tresiba Flextouch U-100Insulin Degludec	93	$92,232
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog	67	$83,165
Fiasp FlextouchInsulin Aspart (Niacinamide)	40	$69,043
Tresiba Flextouch U-200Insulin Degludec	29	$50,954
Humulin R U-500 KwikpenInsulin Regular, Human	19	$46,115
JanuviaSitagliptin Phosphate	30	$39,695
RybelsusSemaglutide	18	$39,007
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog	63	$38,890
Humalog Kwikpen U-200Insulin Lispro	11	$37,610
Novolog FlexpenInsulin Aspart	92	$36,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic, Rybelsus	$1,995	$489,405267 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog	$914	$295,219206 claims
Boehringer IngelheimJardiance	$121	$140,123109 claims
AstraZenecaFarxiga	$663	$110,28089 claims
MerckJanuvia	$12	$39,69530 claims
AbbVieSynthroid	$128	$5,45873 claims
Sanofi-aventis U.S. LLCLantus	$643	$3,49814 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium	$128	$2,412227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Lawrenceville

Tonita WashingtonLawrenceville$153K
Erin HenryLawrenceville$135K
Jennifer BlackLawrenceville$19K
Ashley BeikmannLawrenceville$16K
Allie McAllisterMarietta$299K
Trisha RomanPeachtree City$134K
Lori ReedMarietta$106K
Julia BranchCumming$102K
Hannah BanachWaycross$85K
Morgan GroothandEvans$81K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →